Strong interactions might be seen between miR-146b and CDKN1A, which is an important regulator of cell cycle progression at G1 and can act as a positive regulator of senescence-like terminal proliferation arrest, but its function seems neither sufficient nor absolutely required for a treatment response to doxorubicin in tumor cells, especially soft tissue sarcoma [35]. This evidence concerns the gene CDKN1A and soft tissue sarcoma.